![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
EH Ohlstein, GR Beck , SA Douglas, P Nambi, MA Lago, JG Gleason, RR Ruffolo , G Feuerstein and JD Elliott
Department of Cardiovascular Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania.
The pharmacological characterization of SB 209670, a highly potent nonpeptide endothelin ETA/ETB receptor antagonist was performed. SB 209670 produced concentration-dependent, parallel rightward shifts in the ET-1 concentration-response curves in the isolated rat aorta (ETA receptor-mediated vascular contraction). The Kb for inhibition of ETA receptor-mediated contraction by SB 209670 was 0.4 +/- 0.04 nM. Inhibition by SB 209670 was stereoselective as the (+)-antipode of SB 209670 was approximately 575-fold more potent than the (-)-antipode. Relative to other ET receptor antagonists, the potency of SB 209670 for inhibiting ETA receptor-mediated vascular contraction was 45-, 180- and 775-fold more potent than the ETA selective antagonist BQ-123, or the mixed ETA/ETB receptor antagonists bosentan or PD142893, respectively. The pharmacological antagonism produced by SB 209670 was specific for ET-1. SB 209670 inhibited ETB receptors in the isolated rabbit pulmonary artery as demonstrated by concentration-dependent, parallel rightward shifts in either the ET-1 or sarafotoxin S6c (S6c) concentration-response curves. The Kb values for inhibition were 200 +/- 9 and 52 +/- 14 nM for ET-1 and S6c, respectively. In contrast, neither the ETB selective antagonist RES-701 (10 microM) nor BQ-123 (10 microM) inhibited S6c-mediated vasoconstriction. However, PD 142893 (10 microM) and bosentan (10 microM) produced a small rightward shift in the S6c concentration-response curve, each with Kb values of 1.5 to 3.7 microM. In isolated human circumflex coronary arteries, (+/-)-SB 209670 inhibited ET-1 mediated contraction with a Kb value of 7 +/- 3 nM.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  P. Martin, D. Ninio, and H. Krum Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients With Essential Hypertension Hypertension, March 1, 2002; 39(3): 821 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Burrell, P. Molenaar, P. J. Dawson, and A. J. Kaumann Contractile and Arrhythmic Effects of Endothelin Receptor Agonists in Human Heart In Vitro: Blockade with SB 209670 J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 449 - 459. [Abstract] [Full Text]
|
|
|
|
|
|
C. Wilson, S.-J. Hunt, E. Tang, N. Wright, E. Kelly, S. Palmer, C. Heys, S. Mellor, R. James, and R. Bialecki Pharmacological Profile of ZD1611, a Novel, Orally Active Endothelin ETA Receptor Antagonist J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1085 - 1091. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Iwasaki, M. Notoya, Y. Hayasaki-Kajiwara, T. Shimamura, N. Naya, M. Ninomiya, and M. Nakajima Endothelium-independent vascular relaxation mediating ETB receptor in rabbit mesenteric arteries Am J Physiol Heart Circ Physiol, February 1, 1999; 276(2): H383 - H390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Ohlstein, P. Nambi, D. W. P. Hay, M. Gellai, D. P. Brooks, J. Luengo, J.-N. Xiang, and J. D. Elliott Nonpeptide Endothelin Receptor Antagonists. XI. Pharmacological Characterization of SB 234551, a High-Affinity and Selective Nonpeptide ETA Receptor Antagonist J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 650 - 656. [Abstract] [Full Text]
|
|
|
|
|
|
C. C. Docherty and M. R. Maclean EndothelinB Receptors in Rabbit Pulmonary Resistance Arteries: Effect of Left Ventricular Dysfunction J. Pharmacol. Exp. Ther., March 1, 1998; 284(3): 895 - 903. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. P. Hay, M. A. Luttmann, M. A. Pullen, and P. Nambi Functional and Binding Characterization of Endothelin Receptors in Human Bronchus: Evidence for a Novel Endothelin B Receptor Subtype? J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 669 - 677. [Abstract] [Full Text]
|
|
|
|
|
|
D. W. P. Hay and M. A. Luttmann Nonpeptide Endothelin Receptor Antagonists. IX. Characterization of Endothelin Receptors in Guinea Pig Bronchus With SB 209670 and Other Endothelin Receptor Antagonists J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 959 - 965. [Abstract] [Full Text]
|
|
|
|
|
|
S. A. Douglas, M. Gellai, M. Ezekiel, G. Z. Feuerstein, J. D. Elliott, and E. H. Ohlstein Antihypertensive Actions of the Novel Nonpeptide Endothelin Receptor Antagonist SB 209670 Hypertension, April 1, 1995; 25(4): 818 - 822. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
